|Bid||2.86 x 5000|
|Ask||3.29 x 500|
|Day's Range||2.84 - 2.99|
|52 Week Range||2.69 - 5.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 1, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.79|
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.
Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).
BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.
NEW HAVEN, Conn., Dec. 20, 2017-- In the news release issued earlier today by Achillion Pharmaceuticals, Inc., please be advised the headline should read "Achillion Initiates Phase I First-In-Human ...
NEW HAVEN, Conn., Dec. 20, 2017-- Achillion Pharmaceuticals, Inc., a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the complement alternative pathway, today announced ...
-Orphan drug designation for the treatment of C3G granted by the U.S. -Initiated bioavailability study evaluating extended-release formulations of ACH-4471 in healthy volunteers–. NEW HAVEN, Conn., Dec. ...
Allergan (AGN) signs a definitive contract to acquire Texas-based Repros Therapeutics, which is focused on developing new drugs to treat hormonal and reproductive system disorders.
Merck (MRK) informs that the FDA grants a priority review to its supplemental biologics license application looking for its marketed drug Keytruda's label expansion for a rare lymphoma indication.
Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.
NEW YORK, NY / ACCESSWIRE / December 5, 2017 / U.S. markets saw mixed Monday as the Dow reached a new record after investors celebrated the passing of a bill to overhaul the country's tax system while ...
Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.
Celldex (CLDX) commences a phase I study on CDX-1140 for patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of the candidate at different dose levels.
In May 2015, Johnson & Johnson unit Janssen Pharmaceuticals agreed to develop and commercialize one or more of Achillion Pharmaceuticals’ lead hepatitis C virus (HCV) assets which included ACH-3102, ACH-3422 and sovaprevir. The shares represented a 15.6% stake in Achillion at the time. Such expectations came to an end in early September when Janssen terminated the pact.
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
Agios (AGIO) presents new data from the dose expansion part of a phase I study, evaluating ivosidenib as a single agent for treating IDH1m glioma, at the Society for Neuro-Oncology in San Francisco.
Achillion Pharmaceuticals saw its shares make a handy gain on Thursday after the company announced a secondary offering.
NEW YORK, NY / ACCESSWIRE / November 16, 2017 / U.S. markets dropped sharply Wednesday, with the Dow and S&P 500 posting its largest daily loss since September, as sliding oil prices dragged down the energy ...
NEW HAVEN, Conn., Nov. 15, 2017-- Achillion Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 18,367,346 shares of its common stock by existing stockholder Johnson ...
It was just two months ago when shares of Achillion Pharmaceuticals (ACHN) were crushed by news that its all-important hepatitis C partnership with Johnson & Johnson (JNJ) had come to an end. Today, the drug maker’s share price is in free fall once again, dropping more than 10% in recent market action after Achillion announced that J&J’s venture capital arm, Johnson & Johnson Innovations-JJDC intends to sell its entire stake in Achillion (all 18,367,346 shares) in a secondary offering, and that Achillion will not receive any proceeds. Separately, Achillion released mid-stage data for the experimental drug ACH-4471, a treatment for a rare disease known as C3 glomerulopathy in which protein deposits build up in the patient’s kidneys.
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.